Hims & Hers Health, Inc. (HIMS): A Bull Case Theory

We encountered a bullish thesis on Hims & HERS Health, Inc. In this article, we will summarize the thesis on it. HIMS & HERS HELTH, Inc.^Y June. Hims’s Thering and Forward P/E 77.60 and 86.96, respectively, according to Yahoo’s funding.

A doctor interacts with the patient, discusses his treatment.

HIMS & HERS delivered an unusual Q1 q1, as revenues increased by 111 % year on an annual basis to $ 586 million-the fastest growth in the company ever, and significantly represents the explosive demand on the GLP-1 vehicle. Although the administration expects this contribution to Taper with the availability of Smaglutide on a large scale, it is still expected that the revenues of the entire year will grow more than 60 %, supported by the expanding company’s wallet and the subscriber base.

While the growth of non-GLP-1 revenue slowed to approximately 30 %, this was largely due to the strategic shift in spending on marketing weight loss, which is now reversed. The number of subscribers increased by 38 % to 2.37 million, and the average monthly revenue for each user increased by 53 % on an annual basis, enhancing the economies of strong unit.

Although Q2 guidelines are disappointed, the total margin was contracted to 73 % due to the product mix, the administration expects the margin’s recovery with the stability of international beverage supplies. Meanwhile, the modified Ebitda doubled more than twice to 91 million dollars, and FCF reached $ 50 million despite the increase of Capex – all the signs of strong operational lifting and disciplined capital.

To maintain momentum and support its ambitious goals of 2030 of $ 6.5 billion in revenues and $ 1.3 billion in Ebitda, HIMS focuses on five main growth tools.

First, it is the matter of deepening the allocation, which now affects more than 60 % of the subscribers and has strengthened its retention useful across ancient groups and the latest categories such as skin diseases, weight loss and sexual health.

Second, it expands to highly influential specialties such as hormonal therapy, longevity and early cancer detection, supported by diagnostic acquisitions and a new facility for the manufacture of peptide that targets advanced treatments.

Third, HIMS enhances the capabilities of the basic system through ownership data and artificial intelligence tools such as MedMatch makes care more intelligent, adaptive and attractive.

Fourth, the company selectively cooperates with Blue Chip Pharma, most notably Novo Nordisk, to obtain clinical credibility and expand access to branded drugs. Although organizational translation is continuing, these alliances reduce risks and enhance HIMS as a reliable distribution partner.

Finally, the company is expanding internationally, with early success in the UK in the health of its model abroad. Although insurance partnerships remain outside the table according to the design, which is the low approach to the statute, the first approach to the consumer provides flexibility because it targets other English -speaking markets.